PCRX Stockholders Should Contact Shareholder Rights Firm Robbins For Information About The Class Action Against Pacira Biosciences, Inc.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance ...
sambadenglish12h
IAS officer Satyabrata Rout appointed as Odisha Assembly Secretary
IAS officer Satyabrata Rout has been appointed as the Secretary of Odisha Legislative Assembly. The General Administration ...
PCRX Stockholders Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm ...
devdiscourse1d
Historic Budget Session in Jammu & Kashmir Assembly: A New Era Begins
The Jammu and Kashmir Assembly's budget session commences on March 3 under the new National Conference government led by Omar ...
Pharmabiz1d
March Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma
Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...
Le Lézard1d
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. . Shareholders who purchased shares ...
NYC Summer Rising to return in 2025: Here’s what we know so far
Schools Chancellor Melissa Aviles-Ramos and New York City Department of Youth and Community Development (DYCD) Commissioner ...
2024 Best Real Estate Deals: Announcing the Dealmakers and Rising Stars honorees
The Business Journal is recognizing 12 Rising Stars and Dealmakers this year as part of our 2024 Best Real Estate Deals ...
Targeted Oncology2d
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...